Drug Profile
Visceral leishmaniasis vaccine - IDRI
Alternative Names: LEISH-F3 + GLA-SELatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Bill & Melinda Gates Foundation; Infectious Disease Research Institute
- Developer Gennova Biopharmaceuticals; Infectious Disease Research Institute; Zydus Cadila
- Class Leishmaniasis vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Visceral leishmaniasis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Visceral-leishmaniasis in India (IM, Injection)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Visceral-leishmaniasis(In volunteers) in USA (IM, Injection)
- 01 Apr 2014 Infectious Disease Research Institute initiates enrolment in a phase I trial for Visceral leishmaniasis (prevention) in USA (NCT02071758)